Alkermes starts TRD drug Phase 1/2 trial
ALKS 5461 is the combination of ALKS 33 and buprenorphine. The trial will evaluate the safety, efficacy and pharmacokinetics of ALKS 5461 in 32 patients who are suffering
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.